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Macrophages exposed to endotoxin secrete copious amounts oftumor necrosis
factor a/cachectin (TNF), apotent proinflammatory cytokinethat stimulates poly-
morphonuclear leukocyte (PMN)' adhesion to endothelium (1), phagocytosis, de-
granulation, and oxidant generation (2, 3), as well as endothelial cell procoagulant
activity (4). Though it normally functions to help the host rid itself ofpathogenic
organisms(5), TNF also has the potential, as do otherproinflammatorymediators,
to cause phagocyte damage to host cells. Especially vulnerable in this regard are
host endothelial cells, interposed as they are between activated phagocytes and ex-
travascular tissue. Forexample, large intravenousinfusions ofpurified recombinant
human TNF (rhTNF) reproduce all thecardinal features ofendotoxin-inducedshock
in rats: rapid death from hypotension caused by a diffuse capillary leak syndrome
manifesting as hemoconcentration, tissue edema, and histopathologic evidence of
PMN margination, agglutination, and extravasation (6). On the other hand, mice
whose macrophages are incapable ofproducing TNF in response to endotoxin are
also resistant to endotoxin-induced lethal shock (7). Thus, in pathologic circum-
stances, TNF can provoke a deleterious, even lethal interaction between PMNs, en-
dothelium, and the coagulation cascade.
Eosinophils (EOs) participate, as do PMNs, in a variety ofpathologic inflamma-
tory states reflecting endothelial cell damage, such ascutaneous and systemic vascu-
litis, pneumonitis, and eosinophilic endocarditis (8). Particularly striking is the un-
usual endothelial cell injury that can complicate chronic hypereosinophilic states,
irrespective oftheir cause:: For unclearreasons, the endothelial lining ofthe heart,
theendocardium, is prominently involved, promotingthrombus formationwithem-
bolic sequelae, valvular dysfunction, and mechanical impairment that culminates
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in florid congestive heart failure (9, 10). Hypereosinophilic heart disease, though
rare in Western societies, is estimated to cause 10-20% ofcardiac deaths in tropical
Africa (11), where chronic hypereosinophilia (presumably caused by filariasis and
otherparasitic infestations) is endemic (12). Individuals with hypereosinophilic heart
disease have peripheral blood EOs that show morphologic and metabolic evidence
of activation (13), as well as high serumlevels of potentially cytotoxic eosinophil-
specific granule constituents, such as major basic protein (MBP) (14), suggesting
that endothelial damage results from chronic activation and misapplication of the
potent EO cytotoxic armamentarium. The factor(s) responsible for this activation
are, however, obscure.
TNF is potentially such a factor because it has been shown to stimulate two im-
portant aspects of EO function: adhesion to human endothelium (15) and antibody-
dependent cellular cytotoxicity (ADCC), assayed as killing of antibody-opsonized
schistosomula(16). Moreover, abnormally elevated TNFlevels are detectable in the
serum of humans with chronic parasitic infestations (17), a setting in whichchronic
eosinophilia commonly occurs. We hypothesized that such "pathologically" elevated
concentrations ofTNFmight provoke EO toxicity towardsunopsonized endothelial
cells, and so promote tissue injury in hypereosinophilicstates. We find that concen-
trations of TNF attainable in human disease states stimulate highly,homogeneous
populations ofhuman EOs to damage humanumbilicalvein endothelial cell.(HUVEC)
monolayers, a model of human endothelium. TNF directly influences both en-
dothelium and EOs, rendering HUVEC more susceptible to destruction by acti-
vated EOs and reagent H202, and activating EO generation of cytotoxic oxygen
species. These findings suggest that abnormally elevated serum levels of TNF may
play a role in the pathogenesis oftissue damage in hypereosinophilic states, in part
by simultaneously activating EO oxidant generation while diminishing endothelial
antioxidant defenses.
Materials and Methods
Recombinant Escherichia coli-derived human TNF (rhTNF) was generously supplied by
the Cetus Corp. (Emeryville, CA.) The TNF preparation had a specific activity as assessed
by L929 assay of 2.4 x 101 U/mg protein, andwas >98% pure by SDS-PAGE analysis. The
endotoxincontamination of rhTNF, as assayed by the limulus amoebocyte lysate assay, was
3 pg/1,000,000 U. Therefore, at the concentrations used in the course of thesestudies (<1,000
U/ml) the endotoxin contribution from the TNFpreparation was well below the 1-10 ng/ml
required forprimingofthe PMNrespiratory burst(18). TNFwasheat inactivated by heating
to 90°C. for 15 min (19). Rabbit antiTNF serum, also supplied by Cetus Corp., was pro-
duced by repeated injections of rabbits with rhTNF; a 1:100 dilution of the resulting an-
tiserum neutralized 4,000 U/ml TNF activity in an equal volume. Control serum was ob-
tained from an unimmunizedrabbit.Thetetrapeptide FMLP, superoxide dismutase(SOD),
catalase, Na fluoresceinate, and hydrogen peroxide (30% solution)were obtained from Sigma
Chemical Co. (St. Louis, MO). Percollwas obtained from Pharmacia Fine Chemicals (Pis-
cataway, NJ), PMA from Consolidated MidlandCorp. (Brewster, NY), Earle's buffered salt
solution (EBSS) and HBSS from Gibco Laboratories (Grand Island, NY), FITC mAb Mol
(IgM) from Coulter Immunology (Hialeah, FL), "Cr from Amersham Corp. (Arlington
Heights, IL), methylprednisolone from Upjohn (Kalamazoo, MI), heparinfrom ElkinsSinn,
Inc. (Cherry Hill, NJ), Hetastarch (6% hydroxyethyl starch in normal saline) from DuPont
Co. (Wilmington, DE), and24-wellplates (2 cm2/well) from Costar (Cambridge, MA). The
platelet-activatingfactor inhibitorBN52021 waskindly supplied by Dr. Pierre Braquet(Paris,
France).SLUNGAARD ET AL .
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Eosinophil Purification.
￿
EOs were isolated from peripheral blood (50-200 ml) of individ-
uals with mild to moderate peripheral blood eosinophilia (4-39%) with the following diag-
noses: primary hypereosinophilia (1), allergy (6), Herpes gestationis (1), pulmonary aspergil-
losis-(3), filariasis (2), graft-vs.-host disease (1), asthma (2), and lymphoma (1). Isolation of
EOs was accomplished using a modification of the FMLP-EDTA technique previously de-
scribed by Roberts and Gallin (20). Peripheral blood was obtained by venipuncture and was
drawn directly into 60-cc syringes containing 20 cc of Hetastarch and heparin (10 U/ml).
After sedimenting 30 min at room temperature, the red cell-poor supernatant plasma was
collected.and pelleted at 1,000g for 5 minutes. The resulting leukocyte-free plasma was decanted
and saved, while contaminating red cells in the granulocyte pellet were removed by hypotonic
lysis:followed by two washes in PBS + 0.4% Na citrate (PBS/citrate). Granulocytes were
then resuspended in the leukocyte-free plasma, retained from the previous step, to which
EDTA (0.3% final concentration) had been added. FMLP was added to a final concentration
of 10'6 M, and the cells were incubated 15 min at 37°C in a rocking water bath. Discon-
tinuous Percoll gradients were prepared by diluting iso-osmolar stock Percoll (d = 1.130,
obtained by diluting Percoll with 10 x concentrated PBS, adjusting osmolality to 310 mOsm),
then further diluting with PBS/citrate to obtain solutions with densities of 1.095 and 1.080.
5 ml of the 1.080 solution was layered atop 2 ml of d = 1.095 solution in a 15-ml conical
tube (2095; Falcon Labware, Oxnard, CA). Finally, 5-ml granulocytes suspended in autolo-
gous plasma/EDTA were layered over the d = 1.080 Percoll. Tubes were then spun at 400
g at room temperature for 25 min in a swinging bucket rotor. Cells were then harvested from
the interface between the two different Percoll densities, diluted with PBS/citrate, pelleted,
and washed two times in PBS/citrate. Aliquots of the resulting suspension were used to pre-
pare cytospins, which were subsequently stained with Wright's stain in order to assess EO
purity. The cell yield using this technique was 60-9017o of that present in the sedimented
plasma. EO purity was 85-99.5% (mean 94%); contaminating cells were largely PMNs.
Preparation of HUVECMonolayers.
￿
HUVEC were prepared by collagenase treatment of
umbilical cords as previously described (21). Cells were seeded in 24-well plates (Costar)
(2 cm2 per well) and utilized as primary cultures upon achieving confluence, usually 5-7
d after seeding.
S1Cr Release Cytotoxicity Assay.
￿
Culture medium was aspirated from confluent endothelial
cell monolayers, which were then washed two times in 1 ml of HBSS (37'C). 200 JAIof RPMI
medium containing 1-2 p.Ci of "Cr was layered atop each monolayer, then incubated 2 h
at 37"C in a 5 17b CO2 atmosphere. Tissue culture medium was then aspirated and the cells
washed three times in 1 ml of HBSS, 37'C. After the final wash the labeled monolayers were
overlaid with EBSS containing 5 x 106 EOs and any other reagents in a final volume of 1 ml,
yielding an effector (EO) to target (endothelial cell) ratio of 20-25:1 . EO contact with the
endothelial cell monolayers was ensured by gentle (50 g for 4 min) centrifugation of the 24-
well plates. Inhibitors, such as heparin and methylprednisolone, were added before centrifu-
gation, and agonists, such as TNF and PMA, after centrifugation. Plates were incubated
overnight 16 h at 37'C in a 5% C02 incubator, then centrifuged (1,000 g for 10 min) to pellet
any endothelial cells that may have detached but not lysed. The supernatant fluid was care-
fullyaspirated and 1 ml of 1.0 M NaOH added to solubilize counts in the adherent and pelleted
cells. Supernatant and pellet fractions were counted in a gamma counter. Cytotoxicity was
expressed as percent specific S'Cr release, calculated as follows: percent specific 5'Cr release
= 100 x [(A-C)/(B-C)], where A = cpm in the supernatant of any given well; B = total
counts (pellet + supernatant) in that well; and C = the mean cpm "spontaneous" release
of "Cr into supernatant buffer of four wells containing labeled monolayers and EBSS only.
Typically, spontaneous release was 15-20°76 of the total counts/well. All experiments were
conducted using triplicate or quadruplicate determinations of each treatment group.
AssayofSuperoxideAnionandHOBr Production.
￿
Superoxideanionproductionwas measured
as 'SOD-inhibitable reduction of cytochrome c (22) from EOs adhering to the bottoms of
serum-coated tissue culture plastic wells. 200 11 of FCS was aliquoted into each well of a
24-well, 2-cm2 tissue culture plate. After 0.5 h at 37°C, the serum was aspirated and each
well washed twice with 1 ml of 37°C HBSS. 106 EOs in 1 ml of EBSS containing 75 /AM
cytochrome c was then aliquoted into each well. Contact with the serum-coated plastic well2028
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bottoms was promoted by gentle (50 g for 4 min) centrifugation, after which SOD (20 N4g/ml)
and agonists, such as TNF or PMA, were added. Wells were incubated overnight at 37 °C
in a 5% C02 atmosphere, after which wells were spun at 1,000 g for 10 min to pellet loose
cells, the supernatant fluid was aspirated, and OD550 was measured before and after addi-
tion of a few granules of KFeCN.
HOBr was measured in similar preparations of 106 EOs attached to serum-coated 2-cm2
tissue culture wells by conversion of Na fluoresceinate to eosin yellow (23, 24). Each well
contained a finalvolume of 1 ml EBSS supplemented with 32 p.M sodium fluoresceinate and
1 mM sodium bromide. HOBr production was assayed by pelleting unattached cells (1,000
g for 10 min) and determining supernatant fluid OD5is. The OD5 19 of buffer from control
wells containing all the reagents but no EO was subtracted from each value, and a measured
micromolar extinction coefficient of 0.078 was used to determine molarity of eosin yellow
and, therefore, HOBr production.
FACS Analysis ofCR3(CD11a) Expression.
￿
200,000 cell aliquots of EOs (prepared as above)
or PMNs (prepared by centrifugation of buffy coats over Percoll; d = 1 .075 [25]) were sus-
pended in 100 p,l PBS-0.2% BSA-0.1% sodium azide (PBS-BSA-SA) and incubated 15 min
at 37°C before adding agonists (100 U/ml TNF, 20 ng/ml PMA, or 10-6 M FMLP), and
incubating another 30 min at 37°C. 10 Al of FITC-Mol stock solution (5 1Ag protein) was
then added to the cells by gentle vortexing before incubating 30 min on ice in the dark. La-
beled cells were washed three times in PBS-BSA-SA, suspended in 500,1 PBS-1% paraform-
aldehyde, and stored in the dark at 4°C until analyzed by flow cytometry 2-18 h later. Flow
cytometric analysis of stained leukocytes was accomplished on a Cytofluorograf 50H with
a 2150 computer (Ortho Diagnostic Systems Inc., Westwood, MA) equipped with an argon
(488, 250 mW) and a helium-neon (632.8 nm, 0.8 mW) laser. Gain was monitored daily with
the use of fluorescein-stained calf thymocytes (Fluorotrol; Ortho Diagnostic Systems, Inc.)
and adjusted to give a mean channel fluorescence value of 155. Fluorescence of stained cells
was quantified by assaying right angle greenfluorescence >530 nm on a linear scale. For each
analysis, 10,000 cells were examined; a common setting was used for PMNs and EOs.
Pretreatment ofEosinophils or HUVEC with TNF .
￿
In one of studies, either HUVEC or EOs
were exposed for 4 h to 100 U/ml TNF in isolation before washing away unbound TNF, then
recombining EOs and target cells. HUVEC were exposed to TNF in tissue culture medium
containing 100 U/ml of TNF for 4 h at 37°C under 5% C02 atmosphere, followed first by
aspiration of medium and two washes in 37°C HBSS, then by addition of 5 x 106 untreated
EOs/well. Alternatively, EOs were suspended (2 .5 x 106 cells/ml) in EBSS containing 100 U
TNF/ml, and incubated 4 h at 37°C in a 5% C02 atmosphere with gentle agitation. EOs
were then pelleted and washed two times in large volumes of EBSS before beingresuspended
in EBSS and 5 x 106 EOs layered over each untreated endothelial cell monolayer. Separate
experiments assessed the effects of long-term (18-h) exposure ofendothelial cells to TNF upon
their subsequentvulnerability to killing by activated EOs and H202 . For these experiments,
tissue culture medium was aspirated from all 24 wells of a 24-well plate, then half the wells
were replaced with fresh tissue culture medium and the other half with fresh tissue culture
medium containing 100 U/ml TNF. The plates were incubated overnight at 37°C under a
5% C02 atmosphere. Wells were then aspirated, washed, and labeled with 5'Cr, as described
above, before the addition of 1 ml EBSS or EBSS containing either reagent H202 or EOs
(5 x 106/well) with or without PMA (10 ng/ml).
Statistics.
￿
A student's t test was used to assess the significance ofdifferences between ex-
perimental groups.
Results
As shown in Fig. 1, addition of rhTNF stimulates a dose-dependent increase in
endothelial cell "Cr release caused by EOs from two representative donors (one with
low, the other with high unstimulated [i.e., in the absence of any known stimulus]
toxicity for HUVEC). Although the shapes of the dose-response curves differ, in
both cases, 100 U/ml TNF (a level within the range measurable in serum of patientsSLUNGAARD ET AL.
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FIGURE 1.
￿
Dose-dependent stimulation ofEO damage to HUVEC
by TNF. 2-cmz monolayers of 51Cr-labeled HUVEC were overlaid
with 1 ml EBSS containing the indicated concentrations ofTNF with
no further additions (A) or with 5 x 106 EOs from two different do-
nors ([I and /). After 16 h of incubation, percent specific 51Cr re-
lease was calculated as described in Materials and Methods. An as-
terisk indicates cytotoxicity significantly greater (p < 0.05) than that
in the absence of TNF Error bars t SEM.
with neoplastic diseases and parasitic infestations [17]) significantly increases EO
toxicity forendothelium. 1,000 U/mlTNFfurther stimulates EOtoxicity forHUVEC
without causing significant direct toxicity for HUVEC. However, since this latter
TNF dose is outside the range measured in human disease states, the remainder
ofour cytotoxicity studies were conducted using 100 U/ml rhTNF. Nevertheless, di-
rect toxicity of TNF for endothelium at these concentrations is minimal and be-
comes significant only at levels of 10,000 U/ml or more (not shown).
Pooled results from 16 separate experiments assaying the effect of 100 U/ml TNF
upon EO toxicity for HUVEC are presented in Table I. In aggregate, TNF, which
at this dosedoesnotitselfinjure endothelium, stimulates EO cytolysis ofendothelium
nearly 2.5-fold at the high (20-25:1) E/T ratio used. TNFstimulated EO damage
to endothelium at an 8:1 E/T ratio was 67% of that at 25:1 (not shown). Because
ofthe large variability ofboth unstimulated (10.8 t 12.1% SD specific "Crrelease)
and TNFstimulated (21.4 t 15.6%) EO toxicity in the pooled experiments, and
the contrastingly tight correlation (r = 0.95) between unstimulated and TNF
stimulated EO toxicity for each individual experiment, the cytotoxicity resultshave
been normalized and are expressed as percent that of unstimulated EO for each
endothelial cell plate. To put this magnitude ofTNFstimulated EO toxicity in per-
TABLE I
Effect of TNF on EO Toxicityfor HUVEC
Specific 51CR
release as percent
￿
p Value of
51Cr-labeled monolayers of HUVEC were overlaid with 1 ml EBSS contain-
ing 5 x 106 EOs, EOs with 100 U/ml TNF (EOs + TNF), or EOs + TNF
with the indicated reagents. Specific 51Cr release caused by EOs alone =
100% for each endothelial cell plate. 100 U/ml TNF alone caused 51Cr release
27 t 10% that of EOs.
' vs. EOs.
t vs. EOs + TNF.
Eosinophil preparation that of EOS alone difference
EOs (5 x 106/well)
% t
100
SEM
t 25 -
EOs and TNF (100 U/ml) 243 t 20 < 0.001`
EOs + anti-TNF serum (1 :1,000) 50 t 19 < 0.001t
EOs + control serum (1 :1,000) 185 t 31 NS:
EOs + polymyxin B (1 ng/ml) 245 t 45 NSt2030
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spective, we find that EOs (n = 6)maximallystimulated with 100 ng/ml PMA cause
36 t 12% specific "Cr release. The increased toxicity ofEOs towards endothelium
in the presence of TNF does not represent a direct toxic effect of TNF upon EOs
with consequent release ofcytotoxic EO granule constituents, because EOs recov-
ered from endothelial cell monolayers after overnight incubation in the presence or
absence ofTNFboth retain 90-95% viability, as assessed by trypan blue dye exclu-
sion, and show nogross evidence ofdisruptionordegranulation asassessed inWright-
stained cytospin specimens (not shown). Ofnote, EOs incubated overnight in EBSS
without an endothelial cell monolayer were only 50% viable, thus confirming the
previous observation by Rothenberg et al. (26) that coculture of eosinophils with
endothelial cells greatly increases their longevity.
That TNF, and not someothercontaminant, such asendotoxin, inourTNFprep-
aration was responsible forstimulationofEO toxicity isalso shownin Table I. Serum
from a rabbit immunized against rhTNF significantly attenuates TNFstimulated
EO toxicity forHUVEC, whereascontrol rabbit serum doesnot. Moreover, 1 ng/ml
polymyxin B, which stoichiometrically inactivatesendotoxin (<10 fg/1,000 Uin our
TNF preparation), did not affect TNF/EO toxicity for HUVEC.
To examine mechanisms responsible for TNF-stimulated EO toxicity for en-
dothelium, we assayed the effects of five potential modulators of EO function: (a)
heparin, a polyanionic glycosaminoglycanknown to block the killing of Trypanosoma
cruzi blood stream forms both by EOs(27) and their cytotoxic cationic granule con-
stituent, MBP (28); (b) methylprednisolone, awater-soluble glucocorticoidwithpro-
tean andinflammatoryeffects, including inhibition ofEO chemotaxis (29), blockade
of EO degranulation (30), and, as previously shown by us, parallel attenuation of
C5a-induced EO superoxide production and cytotoxicity for HUVEC (31); (c) su-
peroxide dismutase and catalase, enzymes that act sequentially to catalyze first the
dismutation ofsuperoxide anion to H202, then the two electron reductions ofH202
to H2O; (d) BN52021, a potent inhibitor of the effects of platelet-activating factor
(PAF), an acetherphospholipid metabolite produced by a variety ofcells, including
both EOs (32) andTNFexposed endothelium (33), which is a potent agonist ofEO
respiratory burst activation (34), leukotriene production (34), and degranulation
(35); and (e) 100 ELMBr-, a physiologically relevant concentration ofthis halide (not
normally present in EBSS) which is preferentially oxidized by EO peroxidase (EPO)
but not by PMN peroxidase (MPO) (36). We have shown (37) that the resulting
HOBr is extremelytoxic for severaltypes ofendothelium, including HUVEC, whereas
Br- itself is completely innocuous. Thus, augmentation ofEO toxicity by Br- im-
plicates EPO participation in killing mechanisms. As shown in Fig. 2, both heparin
(10 U/ml) and methylprednisolone (10 ELg/ml) significantly attenuate TNF stimula-
tion ofEOtoxicity forendothelium, whereas SOD/catalase and BN52021 arewithout
discernible effect. In contrast, addition of100 ELM Br- significantly enhances TNF-
stimulated EO killing of endothelium.
Since TNF has been shown to affect directly both endothelium and PMNs, we
next determined whether TNFpromoted EO toxicity for HUVEC was due to iso-
lated effects ofTNF solely uponEOs or, alternatively, endothelialtarget cells. Previous
work has shown that isolated pre-exposure ofeither PMNs or HUVEC to TNFbe-
fore their being combined enhances their subsequent adhesion to each other (1).
Similarly, pre-exposure ofPMNsto TNFfollowed bywashingenhances theirsubse-SLUNGAARD ET AL .
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FIGURE 2.
￿
The effect of five modulators
ofEO cytotoxicitymechanisms upon TNF-
dependentEO toxicity forHUVEC. 2-cm 2
monolayers of 5ICr-labeled HUVEC were
incubated 16 h in the presence of5 x 10 6
EOsand 100U/mlTNF with no further
additions (stippledbars), or further supple-
mented with the following factors (black
bars) : 100AM NaBr (Bromide); 100 pg/ml
superoxide dismutaseand 100 Wg/ml cat-
alase(SOD+CAT); 200AMPAF inhibi-
torBN52021(BN52021) ; 10 U/ml heparin
(Heparin); or 10 lag/ml methylprednisolone
(MP) before determining specific "Cr re-
lease . Mean specific "Cr release ofEOS+ TNF = 100% for each endothelial plate used (n = 3-9
for each factor studied) . An asterisk indicates cytotoxicity significantly different (p< 0.05) from that
ofEO+TNF. Error bars t SEM.
quent lysis ofHUVEC (38) and tumor cells (39) . Accordingly, we exposed either
EOs orHUVEC in isolation to 100 U/ml TNF for 4 h, after which unbound TNF
wasremoved by thorough washing. EOs were then layered overHUVEC monolayers
and incubated 16 h . As shown in the two bars on the right in Fig. 3, preexposure
of either EOs orHUVEC in isolation for 4 h before their being recombined fails
to reproduce the TNFdependent stimulation ofHUVEC killing seen when TNF
was present along with EO for the full 16 h of coincubation (Fig . 3, second barfrom
left) . Thus, in contrast toPMNs (38), EOs are not irreversibly activated to kill unop-
sonized endothelium by prior exposure to TNF.
TNF directly activates an important cytotoxic mechanism ofEOs, the respiratory
burst, but only- when they adhere to "physiologic" surfaces . In studies not shown,
we found that 100 U/ml ofTNF caused scanty NBT reduction in a small (N12%)
proportion ofEOs in stirred suspensions in HBSS. However, the same concentra-
tion ofTNF failed to stimulate a reproducible increase in superoxide anion produc-
tion, assayed as cytochrome c reduction, in stirred suspensions ofMs . BecauseNa-
than (40) has shown that PMNs must first adhere to a "physiologic" surface (e.g .,
serum- or fibronectin-coated plastic ; endothelial cell monolayers) forTNF to stimu-
latePMN superoxide anion production, we studied EOs adhered to the bottom of
FIGURE 3 .
￿
Effect of isolated pre-exposure ofei-
ther EOsorHUVEC to TNFupon subsequent
EO-dependent endothelial cell cytotoxicity. (EO)
5 x 10 EOs/2-cm 2 HUVEC monolayer, 16-h in-
cubation; (EO+TNF) EOS + 100 U/ml TNF,
16 h incubation ; (Pre-exp EO)EOsexposed4 h
to 100 U/ml TNF, then thoroughly washed be-
fore being layered atop untreated HUVEC
monolayers, 16-h incubation thereafter ; (Pre-exp
HUVEC) HUVEC monolayers exposed 4 h to
100 U/ml TNF, thoroughly washed, then over-
laid with untreated EOS, 16-h incubation there-
after. Error bars t SEM.2032
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FCS-coated wells. Under these conditions, addition of 100 U/ml of TNF, but not
heat-inactivated TNF, consistently stimulates a twofold increase ofEO superoxide
anion production (Table II). Indeed, TNFstimulated EOs produce nearly half as
much superoxide anion as EOs maximally stimulated by 100 ng/ml PMA. TNF
stimulates a low-grade, long-term activation of the EO respiratory burst, because
at 4 h, superoxide anion production was only half that measurable after overnight
incubation (not shown) . In parallel studies, 100 U/ml TNF more than doubles EO
production of HOBr, an oxidant generated by EO peroxidase (EPO) from H202
that is farmore potently cytolytic for human endothelium than H202 (37). For per-
spective, 106 TNFstimulated EOs produce N3 nmol HOBr; we have found (manu-
script in preparation) that as little as 6 nmol of EPO-generated HOBr can cause
virtually complete lysis of a 2-cm2 HUVEC monolayer, so that the amount of
HOBr produced by 5 x 106 TNFstimulated EOs is probably capable of causing
significant cytolysis.
InpreviousstudiesofPMNs, TNFhas been found toupregulate cell surface CR3
(CD11b/CD18:C3bireceptor/adherence glycoprotein) expression, stimulate (>50-fold)
phagocytosis of unopsonized zymosan particles by a CR3-dependent mechanism
(2), and increase PMN adherence to HUVEC (1). To determinewhether TNF also
increasesEOCR3 expression, weused FITC-conjugatedMot, amAb with specificity
for the CD11b a subunit of CR3,to perform flow cytometric analysis of purified
(>95%) populations ofPMNs and EOs isolated from the same donors (n = 3). As
shown in Fig. 4 (left), EOs expressMol-reactive epitopetothe same extent as PMNs
before exposure to any known agonist ofphagocyte activation, confirmingprevious
observations by others (41). Moreover, EOs and PMNs are equally capable of up-
regulating CD11b expression, because in response to known agonists (1 UM FMLP
for PMNs, 20 ng PMA for EOs), surface expression of the Mol-reactive epitope
doubles (Fig. 4, right). However, on exposure to 100 U/ml TNF, responses of EOs
and PMNs strikingly diverged: PMN CD11b expression doubles while that ofEOs
is totally unaffected (Fig. 4, middle). This surface receptor analysis was further cor-
roborated in a functional assay, as TNF was found to be without effect upon EO
uptake ofunopsonized zymosan particles (not shown). TNF also failed to affect EO
expression ofLFA-1 andp150,95, two othermembersoftheintegrinfamily (notshown).
TABLE II
TNF Stimulation ofEO 02 - and HOBr Generation
EOs + TNF EOs + HITNF EOs + PMA
Oxidant generated
￿
EOs
￿
(100 U/ml)
￿
(100 U/ml)
￿
(100 ng/ml)
nmol 02-/106 cells/18 h
￿
4.4 t 1 .0
￿
9.4 t 3.2'
￿
4 .5 t 2.8
￿
22.5 t 6.2"
nmol HOBr/106 cells/18 h
￿
1 .3 t 1 .0
￿
2.9 t 1.4'
￿
1 .6 t 1 .2
￿
21 .2 t 4.0'
106 EOs were allowed to adhere to the bottom of 2-cm2 FCS-coated plastic tissue culture
wells in a final volume of 1 ml EBSS. Wells were supplemented with 75 pM cytochrome
c t 20,ug/ml superoxide dismutase for measurement of superoxide anion, and 32 AM sodi-
um fluoresceinate and 1 mM NaBr for measurement of HOBr. After a 16-h incubation at
37° C, the tissue culture plates were spun 1,500 g for 5 min, and supernatant buffer was
aspirated for spectrophotometric determination of 02- and HOBr, as described in Materi-
als and Methods. HITNF, heat-inactivated TNF. Data presented t SD.
p vs. EO < 0.05 .SLUNGAARD ET AL.
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FIGURE 4 .
￿
Flow cytometry analysis ofPMN and
EO CR3 expression detected by Mol (anti-CDllb)
mAb . 200,000 cell aliquots of EOs or PMNs, both
purified to >95% homogeneity (n = 3), were incu-
bated 15 min at 37°C before adding the indicated
agonists, incubated another 30 min at 37°C ., then
exposed to FITC-Mol for 30 min at 4°C before flow
cytometric analysis of 10,000 cells. Unlabeled EOs
andPMNs hadamean channel fluorescence of<5 .
Identical gain settings were used to analyze PMNs
and EOs . Agonists were TNF, 100 U/ml, PMA 20
ng/ml, and FMLP, 10-6M. Error bars t SEM .
Thus, in contrast to PMN, TNF stimulation of increasedEO adhesion toHUVEC
(15) occurs independentlyof increased surface CR3 expression . In PMNs, upregu-
lated surface expression ofthesemolecules reflects mobilization of intracellular pools
(42), suggesting that TNF fails to induce EO degranulation (see Discussion) or that
EO granules do not store integrins .
As well as stimulating various aspects of phagocyte function, TNF also directly
affects diverse aspects of endothelial cell function, for example, their adhesiveness
for PMNs (1), expression of HLA antigens (43), and production of granulocyte/
macrophage-CSF (44) . BecauseTNF induces oxidant damage and reduces antiox-
idant defenses in susceptible tumor cells (45), we determined whetherTNF simi-
larly diminishes antioxidant defenses inHUVEC. As shown in Table III, HUVEC
monolayers exposed 18 h to 100 U/ml TNF release only slightly more "Cr than un-
treated monolayers when subsequently incubated 16 h with buffer alone, 10 ng/ml
ofPMA, or unstimulated EOs. In contrast, TNF (but not heat-inactivated TNF)-
pretreated HUVEC monolayers release more than twice as much "Cr when sub-
sequently exposed to EOs whoserespiratory burst was stimulated by 10 ng/mlPMA.
Because H202 has been shown to be the major oxidant species responsible for
damage toHUVEC by PMA-stimulated PMNs (46), we compared the vulnerability
of control andTNFpretreated HUVEC to a range of reagent H202 concentrations .
As shown in Fig . 5, TNF-pretreated HUVEC are modestly but significantly more
susceptible to lysis by 75 jAM and, especially, 133 pM H202 . In three experiments,
the concentration ofH202 causing half-maximal "Cr release from TNFpretreated
endotheliumwas-50% of that for control endothelium . Thus, exposure ofHUVEC
to subcytolytic and physiologically relevant concentrations ofTNF significantly en-
hances its susceptibility to destruction by activated EOs and H202 .
Discussion
Peripheral blood EOs, normally present at<400 cells/gI, maybe greatly increased
in such disorders as parasitic infestations, allergic or hypersensitivity states, vascu-
litis, andneoplasia (8) . Unfortunately, chronic peripheral blood eosinophilia, irrespec-
tive of its cause, can be complicated by amorbid and often lethal clinical syndrome
characterized by endocarditis, intracardiac capillary damage, andfleeting vasculitic
skin rashes and pulmonic infiltrates, all of which reflect widespread endothelial cell
damage (9, 10, 47) . Immunohistochemical studies demonstrate (48) dense endothelial
deposition ofcytotoxicEO granule constituents, MBP, andEO cationic protein (ECP)2034
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Monolayers of HUVEC were incubated 18 h in tissue culture medium alone (control), or in tissue culture
medium supplemented with 100 U/ml TNF or 100 U/ml heat-inactivated TNF. Monolayers were then
washed, labeled with 51Cr, and incubated 16 h in 1 ml final volume EBSS containing the indicated addi-
tives before determining specific 51Cr release . Data presented t SD.
' p < 0.05 vs. control HUVEC + EBSS buffer.
t p < 0 .001 vs. control HUVEC + PMA + EOs.
from the earliest stages ofthis disease onward, implicatinga deleterious interaction
between EOs and endothelium in the pathogenesis of this disease.
Our findings provide insights potentially relevant to such EO-mediated tissue
damage, in that we have shown that TNF promotes EO toxicity towards human
endothelium, activates the EO respiratory burst, and renders endotheliummore vul-
nerable to oxidant damage. These findings raise the possibility that in the setting
ofchronic peripheralblood hypereosinophilia, increased serumlevels ofTNF might
promote diffuse endothelial damage, including endocarditis. There are a number
ofclinical circumstances in which hypereosinophilia andelevatedlevels ofTNF coexist.
Perhaps the most common would be found in equatorial Africa or Southeast Asia,
where filariasis, and consequently eosinophilia, is endemic together with Loefller's
endocarditis andendomyocardial fibrosis (9). Thoughitis not knownwhether filari-
asis per se is associated with elevated plasma levels of TNF, such common coen-
demic diseases as malaria and trypanosomiasis consistently cause elevated serum
TNFlevels (17). ElevatedTNF and hypereosinophilia mayalso coexist in neoplasia,
either naturally (17) or iatrogenically, as the result of IL-2 infusions, which cause
increased lymphocyte secretion ofTNF as well as high grade eosinophilia (49), or
TNF infusions, which cause a modest eosinophilia (50). Of more widespread rele-
vance, Veith and Butterworth (51) have demonstrated that monocytes derived from
donors with moderate eosinophilia spontaneously secrete into supernatant culture
TABLE III
Vulnerability of TNF-exposed HUVEC to Damage by Activated EOs
0 50 100 300
[H202] (NM)
FIGURE 5.
￿
VulnerabilityofTNFtreated HUVEC to dam-
age by H202. HUVEC monolayers exposed 18 h to 100
U/ml TNF, then thoroughly washed, 51Cr-labeled, and in-
cubated another 16 h in 1 ml EBSS with the indicated con-
centrations of reagent H202. (p) Control HUVEC; (0)
TNFexposed HUVEC. An asterisk indicates cytotoxicity
significantly different (p < 0.05) from that of control
HUVEC. Error bars t SD.
Endothelial cell preparation EBSS buffer
Specific
PMA
(10 ng/ml)
5'Cr release
EOs
(5 x 106) EOs + PMA
Control HUVEC 0.0 t 2 .1 0.8 t 0.3 5.3 t 2.1 20.6 t 5.4
HUVEC exposed 18 h to TNF (100 U/ml) 4.1 t 2 .1* 1 .8 t 0.4 7.3 t 1 .2 55.5 f 2.21
HUVEC exposed 18 h to heat-inactivated
TNF (100 U/ml) 3.9 t 0.9' ND ND 20.2 t 2.6SLUNGAARD ET AL.
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medium afactor capable ofstimulatingantibody-dependent cytotoxicityforthe schis-
tosomula of Schistosoma mansoni. Amajor componentofthis supernatant activity was
subsequently found to be TNF (16). If these in vitro data can be extrapolated in
vivo, peripheralblood eosinophilia maytypicallybe accompanied byincreasedserum
levels of TNF
To validate our in vitro studies, we have considered three possible artifacts. First,
TNF stimulationofEOdamage to HUVEC could reflectendotoxin contamination
ofour rhTNF preparation. Although endotoxin alone in concentrations >1 wg/ml
provokes minimal PMN damage to endothelial cells, pretreatment of PMNs with
endotoxin in much lower doses (1-10 ng/ml) greatly potentiates("primes") endothelial
damage caused by subsequent addition ofagonists such as 10' MFMLP (18). We
consider it highly unlikely that endotoxin in our TNF preparation was responsible
for its stimulation of EO toxicity to human endothelial cells because: (a) our TNF
preparation contains <10 fg endotoxin/1,000 U and a several order of magnitude
ofexcess polymyxin B (Table I) was without effect; (b) our TNF preparation, unlike
endotoxin, loses its activity when heated for 15 min at 90°C (Tables II and III);
and (c) antiTNF rabbit serum attenuates TNFstimulated EO toxicity for human
endothelial cells, whereas control rabbit serum does not. We cannot, however, rule
out the possibility that endotoxin contaminating our medium and buffers could
somehow have "primed" EOs to respond to TNF.
Second, TNFstimulated EO toxicity towards endothelium may be an artifact of
prior exposure of EOs to FMLP during the isolation procedure. Yazdanbakhsh et
al. (52) have shown that EOs prepared by a discontinuous Percoll gradient tech-
nique inthe absence ofFMLP activatetheir respiratory burstin response to FMLP,
though to a much lower level than PMNs. Inaddition, pre-exposure ofEOsto FMLP
potentiated their subsequent response to PMA (52), suggesting that priorexposure
to FMLPmight likewiseprimeEOs torespondto other agonists, such asTNF How-
ever, when we isolated EOs from peripheral blood by the alternative procedure de-
scribed byYazdanbakhsh etal., (52), theyresponded to 100 U/ml TNFwith a similar
degree ofenhanced cytotoxicity towards endotheliumas EOs isolatedby ourFMLP
technique(250 t 30% vs. 243 t 20%; n = 3). Similarly, EOs isolated fromadonor
with primary hypereosinophilia, whose chronic 90-9817o eosinophilia allowed pu-
rification on a one-step Percoll gradient (d = 1.077)withoutprior exposure toFMLP,
showed a similar degree ofenhanced cytotoxicity towards human endothelium in
the presence ofTNF (210 t 639o; n = 4). Nonetheless, we acknowledge that since
the majority ofour EO donors had significant eosinophilia, we cannot be certain
that ourfindingscouldbe replicated using EOsfrom persons withnormal EOcounts.
However, no correlation was evident between the magnitude ofTNF stimulation
of EO endothelial killing or oxidant production and degree of eosinophilia over a
wide range from 4 to 39% (not shown).
Finally, it is possible that small numbers ofPMNs contaminatingour EO prepa-
rations were responsible forgenerating the increase in superoxide anion and HOBr
measurable after exposure of EOs to TNF (Table 11). We consider this highly im-
probable because: (a) PMN contamination ofEO specimens varied between <1 and
15%, yet the degree of stimulation was similar in all the experiments (not shown);
(b) the productionofsuperoxide anion in these minimally contaminated EO prepa-
rations is (on a per cell basis) twice that reported by Larrick et al. (3) for purified2036
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populations of PMN; (c) activated EOs, but not PMNs, produce HOBr instead of
HOCI in the presence of 150 mM Cl- and 100 AM Br` (36); and (d) TNF stimu-
lates NBT dye reduction in individual EOs (not shown) .
In considering mechanisms by which TNF-exposed EOs provoke endothelial cell
injury, we have shown that TNF stimulates surface-adherent EOs to produce su-
peroxide anion and the EO-specific, cytotoxic oxidant HOBr; however our data do
nounequivocally establish arole forthese oxidants in causing endothelial celldamage.
In fact, superoxide dismutase and catalase, which should theoretically "scavenge"
superoxide anion and H202, had no effect upon TNF/EO-mediated endothelial cell
killing (Fig. 2). However, this result does not rule out an important contribution
by oxidants tothe killing mechanism, since these high molecularweight scavenging
proteins may not gain access to the space between endothelial cells and attached
EOs. Moreover, any HOBr generated by EOs intracellularly could subsequently
freely diffuse to causetarget cell damage impervious tothe scavenging effect ofcata-
lase. Indeed, Vissers et al. (53) have shown that PMNs adherent toglomerularbase-
ment membranes containing IgG aggregates produce considerable amounts of
H202 in the contact area between the cells and target basement membrane but re-
lease no detectable extracellular (and therefore scavengeable) 02-. Moreover, Pincus
et al. (54) have shown that supernatant medium from cultured blood mononuclear
cells, which contains TNF (16), enhances EO ADCC towards schistosomula by a
mechanism that is oxygen dependent yet not inhibitable by superoxide dismutase
and catalase. Considering that PMN (40) and EO adherence to biologic surfaces
potentiates TNF activation ofthe respiratoryburst, "polarized" or contact-localized
oxidant generation in a sequestered space, such asthat described above, would serve
auseful purpose toexclude potentialscavenging substancesandfocusoxidantdamage
to an attached target while sparing surrounding host cells. Compatible with this hy-
pothesis is the ability ofTNF to stimulate EO toxicity towards endothelium in the
presence of serum, which is normally a potent scavenger ofreactive oxidants (EOs
in EBSS, 6.6% specific "Cr release; EOs + 100 U/ml TNF in EBSS, 47.9%; EOs
in EBSS + 10% FCS, 2.0%; EOs + TNF in EBSS + 10% FCS, 24.6%; TNF in
EBSS + 10% FCS, 0.6%).
In addition to their potent oxygen-dependent cytotoxic capacities, EOs also use
highly effective oxygen-independent killing mechanisms. Forinstance, EOs kill schis-
tosomula by a peroxidase-dependent mechanism in the presenceofoxygen (55), yet
can kill just as effectively in an anaerobic environment (56). Oxygen-independent
toxicity is mediated by EO-specific granulecationic proteins, including MBP, ECP,
and eosinophil-derived neurotoxin, which are all directly cytolytic for a variety of
metazoan and mammalian cells (57). IfTNF could induce degranulation of EOs,
then these cationic proteins might damage adjacent endothelial cells independent
of oxidant mechanisms. However, we find that only nonphysiologic, high (10,000
U/ml) concentrations ofTNF induce EO degranulation, assayed as release of EPO
into supernatant buffer (not shown). Nonetheless, the possibility remains that at
thelowerTNF doses usedin the course ofour studies, localizeddegranulation, similar
to localized oxidant production as described above, contributes to EO endothelial
cell damage. The capacity of heparin, which blocks the toxicity of MBP (28), to
inhibit TNF/EO-mediated endothelial cytotoxicity (Fig. 2) suggests this may be so.SLUNGAARD ET AL.
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In addition to stimulating EOoxidant production,wealsofindTNF directly affects
endothelial cells, enhancingtheirvulnerability to damage by PMA-stimulated EOs,
perhaps, in part, by increasing their susceptibility to lysis by H202. Alternatively,
enhanced cytolysis ofTNFexposed endothelium may reflect increased adhesion of
EOs, since TNF treatment ofendothelium is known to enhance subsequent EO at-
tachment by aCD11/CD181eukocyte adherence glycoprotein-dependent mechanism
inhibitable by mAb 60.3 (15). However, wedoubt this mechanism is important, be-
causein studies not shown, thisantibody (50 wg/ml) does notattenuate the increased
cytolysis of TNF-treated endothelium by PMA-stimulated EOs. Instead, we pro-
pose that TNF treatment ofhuman endotheliumdecreases itsantioxidantdefenses,
thereby renderingit more susceptibleto killingby EOs activatedby PMA, a potent
respiratory burst stimulant. That TNFexposed HUVEC are also more damaged
by H202 (Fig. 5) and FMLP- and PMA-stimulated PMN (not shown) supports this
interpretation. Moreover, Varani et al. (58) have previously shown that rat pulmo-
nary artery endothelium pre-exposed to TNF is morevulnerable to damage byC5a-
and PMA-activated PMN, raising the possibility that this phenomenon may be a
generalized response ofendothelium to TNF Also compatible with our hypothesis
are the data of Zimmerman et al. (45), which show that in the L929 tumor line,
acute exposure to TNF causes accumulation of oxidized glutathione (GSSG) and
a drop in the glutathione/GSSG ratio, indicating TNF mediates both ongoing ox-
idant production and diminished oxidant buffering capacity. As it is unlikely that
the modestly enhanced vulnerability ofTNF pretreated endothelium to bolus H202
(Fig. 5) accounts entirely for its increased susceptibility todamage by phagocytes whose
respiratory bursthasbeen activated(Table III), we are currentlycharacterizing theeffect
ofTNF exposure upon several endothelial cellantioxidant defenses, includingNADPH,
catalase, superoxide dismutase, GSH, and glutathione peroxidase levels.
Regardlessofthe precisemechanism involved, ourobservationthatexposure ofhuman
endothelial cellsto TNFenhancestheirvulnerabilitytodamage by activatedEOs, PMNs,
and H202 has obvious implications for the pathogenesis of clinical syndromes in-
volving phagocyte-dependent endothelial damage. For instance, in chronic
hypereosinophilic states associatedwith widespread endothelial damage, peripheral
blood EOs are activated, spontaneously producing cytotoxic oxidants (59). In this
setting, elevated serum TNF couldboth further activate EO oxidant production and
concomitantly render endothelium more vulnerable to damage by these same cells,
thereby producingasynergisticeffect upon endothelialcelltoxicity. Endotoxin-induced
shock and the localized Shwartzmann reaction, both mediated at least in part by
TNF (5, 60), may similarly reflect the capacity ofTNF not only to activate phago-
cytes but also todiminish thecapacity ofendothelial cells towithstand theironslaught.
Finally, wenotethatTNF stimulation ofEOtoxicity towards unopsonizedhuman
endothelium occurs at TNF concentrations orders ofmagnitude more (100 vs. 0.01
U/ml) than those that stimulate ADCC towards antibody-opsonized schistosomula
(16). This difference may indicate the existence of a wide therapeutic "window" of
concentrations in which TNF normally functions beneficially to aid EOs rid the
host of parasites. However, abnormally elevated TNF levels, such as occur (5) in
response to chronic intracellular parasitic infestations, malignancy, or endotoxinemia,
may provokecirculatingEOsto damagehost endothelium withadverseclinical con-
sequences.2038
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Summary
Eosinophils (EOs) participate in a variety of inflammatory states characterized
by endothelial cell damage, such as vasculitis, pneumonitis, and endocarditis. We
find that 100 U/ml TNFa/cachectin (TNF), a concentration attainable in the blood
ofhumans with parasitic infestations, stimulates highly purified populations of EOs
to damage human umbilical vein endothelial cells (HUVEC), a model of human
endothelium. This TNFdependent EO cytotoxicity is strongly inhibited by heparin
and methyprednisolone but unaffected by the platelet-activating factor antagonist
BN52012 or scavengers of superoxide anion and H202, superoxide dismutase and
catalase. However, addition of a physiologically relevant concentration of Br- (100
/AM) enhances EO/TNF damage to HUVEC, implicating the possible participation
of EO peroxidase (EPO) in the killing mechanism. EOs adherent to FCS-coated
plastic wells more than double their production of superoxide anion and the cyto-
toxic EPO-derived oxidant HOBr when exposed to TNF, showing that TNF acti-
vates the respiratory burst of EOs attached to a "physiologic" surface. Unlike PMNs,
EOs were not irreversibly activated to kill unopsonized endothelium by previous
exposure to TNF, and did not degranulate or upregulate CR3 expression as de-
tected by Mol in the presence of 100 U/ml TNF. HUVEC exposed 18 h to TNF
were considerably more susceptible to lysis by PMA-activated EOs and reagent
H202, demonstrating a direct effect of TNF upon endothelium, perhaps through
inhibition of antioxidant defenses. These findings suggest that abnormally elevated
serum levels of TNF may provoke EOs to damage endothelial cells and thereby play
a role in the pathogenesis of tissue damage in hypereosinophilic states.
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